Type your tag names separated by a space and hit enter

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

Abstract

BACKGROUND

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and delaying disease worsening is a relevant treatment outcome.

METHODS

Data from 6 randomized, double-blind, placebo-controlled, 6-month studies were pooled and a subgroup of patients (867 on placebo, 959 on memantine) with moderate to severe AD (Mini- Mental State Examination <20) was analyzed. 'Any clinical worsening' was defined as a decline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) or the Severe Impairment Battery (SIB) and on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) and the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), and 'marked clinical worsening' as > or = 4 points decline on the ADAS-cog or > or = 5 points on the SIB and decline on the CIBIC-plus and the ADCS-ADL.

RESULTS

More placebo-treated than memantine-treated patients showed any clinical worsening (28 vs. 18%; p < 0.001), and 21% placebo-treated patients compared to 11% memantine-treated patients had marked clinical worsening (p < 0.001).

CONCLUSION

In this population of moderate and severe AD patients, treatment with memantine was associated with reducing worsening of clinical symptoms in AD during the 6-month study period.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK. david.wilkinson@wht.nhs.uk

    Source

    MeSH

    Activities of Daily Living
    Aged
    Aged, 80 and over
    Alzheimer Disease
    Disability Evaluation
    Disease Progression
    Double-Blind Method
    Excitatory Amino Acid Antagonists
    Female
    Humans
    Male
    Memantine
    Mental Status Schedule
    Neuropsychological Tests
    Nootropic Agents
    Randomized Controlled Trials as Topic

    Pub Type(s)

    Journal Article
    Meta-Analysis
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    17622761

    Citation

    Wilkinson, David, and Henning Friis Andersen. "Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients With Moderate to Severe Alzheimer's Disease." Dementia and Geriatric Cognitive Disorders, vol. 24, no. 2, 2007, pp. 138-45.
    Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(2):138-45.
    Wilkinson, D., & Andersen, H. F. (2007). Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 24(2), pp. 138-45.
    Wilkinson D, Andersen HF. Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients With Moderate to Severe Alzheimer's Disease. Dement Geriatr Cogn Disord. 2007;24(2):138-45. PubMed PMID: 17622761.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. AU - Wilkinson,David, AU - Andersen,Henning Friis, Y1 - 2007/07/04/ PY - 2007/05/28/accepted PY - 2007/7/12/pubmed PY - 2007/11/1/medline PY - 2007/7/12/entrez SP - 138 EP - 45 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 24 IS - 2 N2 - BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and delaying disease worsening is a relevant treatment outcome. METHODS: Data from 6 randomized, double-blind, placebo-controlled, 6-month studies were pooled and a subgroup of patients (867 on placebo, 959 on memantine) with moderate to severe AD (Mini- Mental State Examination <20) was analyzed. 'Any clinical worsening' was defined as a decline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) or the Severe Impairment Battery (SIB) and on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) and the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), and 'marked clinical worsening' as > or = 4 points decline on the ADAS-cog or > or = 5 points on the SIB and decline on the CIBIC-plus and the ADCS-ADL. RESULTS: More placebo-treated than memantine-treated patients showed any clinical worsening (28 vs. 18%; p < 0.001), and 21% placebo-treated patients compared to 11% memantine-treated patients had marked clinical worsening (p < 0.001). CONCLUSION: In this population of moderate and severe AD patients, treatment with memantine was associated with reducing worsening of clinical symptoms in AD during the 6-month study period. SN - 1420-8008 UR - https://www.unboundmedicine.com/medline/citation/17622761/Analysis_of_the_effect_of_memantine_in_reducing_the_worsening_of_clinical_symptoms_in_patients_with_moderate_to_severe_Alzheimer's_disease_ L2 - https://www.karger.com?DOI=10.1159/000105162 DB - PRIME DP - Unbound Medicine ER -